EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Pleuroparenchymal fibroelastosis from a rheumatologic perspective

Maximiliano Diaz Menindez iD, Alejandro Diaz Arumir Vergara, Vivian Shing, Carolyn Mead Harvey, Ana C Zamora Martinez, Vivek Nagaraja

Therapeutic Advances in Respiratory Disease · 2026-05 · 20

DOI: 10.1177/17534666261445202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 06.05.2026. Verfasst von Maximiliano Diaz Menindez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Scleroderma, Systemic, Rheumatic Diseases, Autoimmune Diseases. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pleuroparenchymal fibroelastosis (PPFE) is a rare interstitial lung disease (ILD) associated with systemic autoimmune rheumatic diseases (SARDs). Its clinical characteristics and outcomes in SARDs remain poorly defined.

Objectives

To describe demographics, imaging patterns, and outcomes in SARD-associated PPFE.

Methods

Patients diagnosed with PPFE and SARDs at Mayo Clinic (2000-2024) were included. PPFE diagnosis was confirmed by high-resolution computed tomography, and SARD diagnoses were established by rheumatologists.

Results

Fifteen of 62 patients with PPFE had SARDs with majority having systemic sclerosis (SSc)(n= 7, 46%). Median age at PPFE diagnosis was 57.2 years; 80% were female; 40% were ever-smokers; 40% required supplemental oxygen; 5 had pulmonary hypertension. Coexisting ILD patterns included UIP (26.7%) and NSIP (20%). Coexisting ILD patterns included usual interstitial pneumonia (26.7%) and nonspecific interstitial pneumonia (20%). Three patients died, including two with SSc.

Conclusion

Systemic sclerosis was the most frequently observed SARD among patients with PPFE, and may coexist with other ILD patterns; recognition may inform risk stratification, multidisciplinary evaluation, and longitudinal follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialScleroderma, SystemicRheumatic DiseasesAutoimmune DiseasesPulmonary FibrosisHumansFemaleTomography, X-Ray ComputedMiddle AgedMaleAgedRetrospective StudiesAdult

Stichwörter der Autor:innen

ILDPPFESARDSconnective tissue diseasespleuroparenchymal fibroelastosis

Autor:innen und Institutionen

  • Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA.
  • Division of Pulmonary and Sleep Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA.
  • Mayo Clinic Alix School of Medicine, Phoenix, AZ, USA.
  • Division of Rheumatology, Mayo Clinic Arizona, 13400 E Shea Boulevard, Scottsdale, AZ 85259, USA.

ORCID-Profile: Maximiliano Diaz Menindez

Zitieren

APA

Diaz Menindez, M., Diaz Arumir Vergara, A., Shing, V., Mead Harvey, C., Zamora Martinez, A. C., & Nagaraja, V. (2026). Pleuroparenchymal fibroelastosis from a rheumatologic perspective. Therapeutic Advances in Respiratory Disease, 20. https://doi.org/10.1177/17534666261445202

Vancouver

Diaz Menindez M, Diaz Arumir Vergara A, Shing V, Mead Harvey C, Zamora Martinez AC, Nagaraja V. Pleuroparenchymal fibroelastosis from a rheumatologic perspective. Therapeutic Advances in Respiratory Disease. 2026;20. doi:10.1177/17534666261445202

BibTeX
@article{DiazMenindez2026,
  author = {Diaz Menindez, Maximiliano and Diaz Arumir Vergara, Alejandro and Shing, Vivian and Mead Harvey, Carolyn and Zamora Martinez, Ana C and Nagaraja, Vivek},
  title = {Pleuroparenchymal fibroelastosis from a rheumatologic perspective},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2026},
  volume = {20},
  doi = {10.1177/17534666261445202}
}
Kostenlos starten →